Palmero-Picazo J, Lassard-Rosenthal J, Ríos-Zavala E

Language: Spanish
References: 12
Page: 88-94
PDF size: 189.52 Kb.

ABSTRACT

Introduction: the use of blood transfusions leads to increased hospital costs and an increased risk of medical complications and death. Therefore, it is necessary to study the incidence of major bleeding events and the factors associated with these outcomes in patients undergoing primary total hip arthroplasty (THA). Material and methods: observational, longitudinal and prospective study, carried out at the High Specialty Medical Unit of Traumatology and Orthopedics of Lomas Verdes of the Mexican Institute of Social Security, in the Joint Replacement Service, in the period from March 1, 2020 to July 1, 2020. Results: the incidence of major bleeding in patients undergoing primary THA was 84.8%, when considering two criteria: a decrease in hemoglobin ≥ 2 g/dl and the need for transfusion ≥ 2 units of red blood cells. This figure increased to 87.1% when also including trans-surgical bleeding at its 75th percentile, equivalent to 500 ml. Transfusion of at least one unit of red blood cells during surgery was performed in 68% of patients. Trans-surgical bleeding reached a maximum of 1,900 ml, with a 75th percentile of 500 ml. Unlike other studies, in our institution, female gender did not prove to be a significant risk factor for major bleeding. Conclusion: it is advisable to analyze the procedures and particularities of THA surgery that may be associated with a lower risk of bleeding in older patients.

REFERENCES

1. Quintero JI, Cardenas LL, Navas M, Bautista MP, Bonilla GA, Llinas AM. Primary joint arthroplasty surgery: is the risk of major bleeding higher in elderly patients? a retrospective cohort study. J Arthroplasty. 2016; 31(10): 2264-8.

2. Torres-Gómez A, Mallen-Trejo A. Factores asociados a un sangrado mayor en reemplazo total de cadera. Acta Ortop Mex. 2015; 29(5): 245-50.

3. Guideline on clinical investigation of medicinal products for the treatment of venous thromboembolic disease. EMA/CHMP/41230/2015. Committee for Medicinal Products for Human Use (CHMP), editor. London: European Medicines Agency; 2016.

4. Oberweis BS, Nukala S, Rosenberg A, Guo Y, Stuchin S, Radford MJ et al. Thrombotic and bleeding complications after orthopedic surgery. Am Heart J. 2013; 165(3): 427-33.e1.

5. Hochreiter J, Hejkrlik W, Emmanuel K, Hitzl W, Ortmaier R. Blood loss and transfusion rate in short stem hip arthroplasty. A comparative study. Int Orthop. 2017; 41(7): 1347-53.

6. Carling MS, Jeppsson A, Eriksson BI, Brisby H. Transfusions and blood loss in total hip and knee arthroplasty: a prospective observational study. J Orthop Surg Res. 2015; 10: 48.

7. Mitchell MD, Betesh JS, Ahn J, Hume EL, Mehta S, Umscheid CA. Transfusion thresholds for major orthopedic surgery: a systematic review and metaanalysis. J Arthroplasty. 2017; 32(12): 3815-21.

8. Spyropoulos AC, Anderson FA Jr., FitzGerald G, Decousus H, Pini M, Chong BH, et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011; 140(3): 706-14.

9. Decousus H, Tapson VF, Bergmann JF, Chong BH, Froehlich JB, Kakkar AK, et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest. 2011; 139(1): 69-79.

10. Reglamento de la Ley General de Salud en Materia de Investigación para la Salud. Presidencia de la República, editor. México, DF: Diario Oficial de la Federación; 2014.

11. Declaración de Helsinki de la AMM - Principios éticos para las investigaciones médicas en seres humanos, adoptada por la 64ª Asamblea General, Fortaleza, Brasil, octubre 2013. World Medical Association, editor. Francia: Asociación Médica Mundial - WMA; 2015.

12. Velasco-Rodríguez VM, Martínez-Ordaz VA, Roiz-Hernández J, Huazano-García F, Nieves- Rentería A. Muestreo y tamaño de la muestra: una guía práctica para personal de salud que realiza investigación. Velasco-Rodríguez VM, editor. Buenos Aires: e-libro.net; 2003.

EVIDENCE LEVEL

II.